If approved, Vyvgart Hytrulo (efgartigimod alfa) will be the first drug in the FcRn blocker class to treat CIDP, a rare autoimmune disease of the peripheral nervous system that causes fatigue ...

The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.A recent comprehensive analysis of the Chronic ...

Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase) is the first drug in the FcRn blocker class to treat CIDP, a rare autoimmune disease of the peripheral nervous system that causes fatigue ...

She highlighted that 25% of CIDP prescribers were first-time VYVGART users ... TED, ITP, and Sjogren’s disease. Product net sales for Q4 totaled $737 million, with a full-year total of $2.2 billion.

The biotech put the message out in a direct-to-consumer TV ad that paints Vyvgart Hytrulo as a drug that can help people with chronic inflammatory demyelinating polyneuropathy (CIDP) live life to ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported ...

Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25Phase 3 CAPTIVATE trial of ...

Feb. 28, 2025 /PRNewswire/ -- The GBS | CIDP Foundation International today ... The report's release coincides with Rare Disease Day, a global initiative to raise awareness and generate support ...

She highlighted that 25% of CIDP prescribers were first-time VYVGART ... ITP, and Sjogren’s disease. Product net sales for Q4 totaled $737 million, with a full-year total of $2.2 billion.